{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:46:14Z","timestamp":1789487174874,"version":"build-2803163510"},"reference-count":212,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["23-65-00003"],"award-info":[{"award-number":["23-65-00003"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"award":["23-65-00003"],"award-info":[{"award-number":["23-65-00003"]}],"id":[{"id":"https:\/\/ror.org\/03y2gwe85","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Sci.","Medical Sciences"],"abstract":"<jats:p>Leiomyosarcoma (LMS) is a rare, aggressive soft-tissue sarcoma arising from smooth muscle cells. It has a high metastatic potential and limited therapeutic options. Despite advances in oncology, the molecular landscape of LMS remains incompletely understood, particularly regarding the genetic and epigenetic alterations that affect key signaling pathways. This review summarizes the current knowledge of mechanisms driving LMS pathogenesis, including somatic mutations in genes such as TP53 and RB1, chromosomal instability, dysfunction of DNA damage response and repair, aberrant DNA methylation, histone modifications, and non-coding RNAs. Emerging treatment strategies include inhibitors of PI3K\/AKT\/mTOR and CDK4\/6 signaling, epigenetic drugs, immunotherapy, and combinations of these approaches. However, the coexistence of multiple genetic abnormalities complicates diagnosis, prognosis, and therapeutic selection. Companion diagnostic tools that test candidate therapies ex vivo or in vitro may help exclude potentially ineffective targeted treatments.<\/jats:p>","DOI":"10.3390\/medsci14050571","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:33:42Z","timestamp":1789479222000},"page":"571","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Vulnerabilities of the Key Genetic Drivers in Leiomyosarcoma"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1967-9637","authenticated-orcid":false,"given":"Ekaterina A.","family":"Lesovaya","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Mechanisms of Chemical Carcinogenesis, Institute of Experimental Oncology and Carcinogenesis, N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia"},{"name":"Faculty of Oncology, I.P. Pavlov Ryazan State Medical University, Ministry of Health of Russia, 9 Vysokovol\u2019tnaya St., Ryazan 390026, Russia"},{"name":"Institute of Medicine, Peoples\u2019 Friendship University of Russia, 6 Miklukho-Maklaya St., Moscow 117198, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timur I.","family":"Fetisov","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Mechanisms of Chemical Carcinogenesis, Institute of Experimental Oncology and Carcinogenesis, N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beniamin Yu.","family":"Bokhyan","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Mechanisms of Chemical Carcinogenesis, Institute of Experimental Oncology and Carcinogenesis, N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0896-2952","authenticated-orcid":false,"given":"Varvara P.","family":"Maksimova","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Mechanisms of Chemical Carcinogenesis, Institute of Experimental Oncology and Carcinogenesis, N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny P.","family":"Kulikov","sequence":"additional","affiliation":[{"name":"Faculty of Oncology, I.P. Pavlov Ryazan State Medical University, Ministry of Health of Russia, 9 Vysokovol\u2019tnaya St., Ryazan 390026, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennady A.","family":"Belitsky","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Mechanisms of Chemical Carcinogenesis, Institute of Experimental Oncology and Carcinogenesis, N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8599-6833","authenticated-orcid":false,"given":"Kirill I.","family":"Kirsanov","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Mechanisms of Chemical Carcinogenesis, Institute of Experimental Oncology and Carcinogenesis, N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia"},{"name":"Institute of Medicine, Peoples\u2019 Friendship University of Russia, 6 Miklukho-Maklaya St., Moscow 117198, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9710-8178","authenticated-orcid":false,"given":"Marianna G.","family":"Yakubovskaya","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Mechanisms of Chemical Carcinogenesis, Institute of Experimental Oncology and Carcinogenesis, N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia"},{"name":"Institute of Medicine, Peoples\u2019 Friendship University of Russia, 6 Miklukho-Maklaya St., Moscow 117198, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e35772","DOI":"10.1002\/cncr.35772","article-title":"Clinician\u2019s Primer for Soft Tissue Sarcomas: Nuances of Histologic Subtypes","volume":"131","author":"Wisdom","year":"2025","journal-title":"Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00330-008-1292-3","article-title":"Soft Tissue Sarcomas at a Glance: Clinical, Histological, and MR Imaging Features of Malignant Extremity Soft Tissue Tumors","volume":"19","author":"Kliffen","year":"2009","journal-title":"Eur. Radiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1038\/modpathol.2015.139","article-title":"Practical Issues in Uterine Pathology from Banal to Bewildering: The Remarkable Spectrum of Smooth Muscle Neoplasia","volume":"29","author":"Oliva","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.clon.2009.07.016","article-title":"Pathology of Soft Tissue Sarcomas","volume":"21","author":"Thway","year":"2009","journal-title":"Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/his.12466","article-title":"Progressive Loss of Myogenic Differentiation in Leiomyosarcoma Has Prognostic Value","volume":"66","author":"Demicco","year":"2015","journal-title":"Histopathology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"103955","DOI":"10.1016\/j.critrevonc.2023.103955","article-title":"The Biology and Treatment of Leiomyosarcomas","volume":"184","author":"Kerrison","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Yang, Q., Madueke-Laveaux, O.S., Cun, H., Wlodarczyk, M., Garcia, N., Carvalho, K.C., and Al-Hendy, A. (2024). Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy. Cells, 13.","DOI":"10.3390\/cells13131106"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/dc.23540","article-title":"Primary Pancreatic Leiomyosarcoma with Metastasis to the Liver Diagnosed by Endoscopic Ultrasound-guided Fine Needle Aspiration and Fine Needle Biopsy","volume":"44","author":"Reyes","year":"2016","journal-title":"Diagn. Cytopathol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Spari\u0107, R., Andji\u0107, M., Babovi\u0107, I., Nejkovi\u0107, L., Mitrovi\u0107, M., \u0160tuli\u0107, J., Pupovac, M., and Tinelli, A. (2022). Molecular Insights in Uterine Leiomyosarcoma: A Systematic Review. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23179728"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"iv51","DOI":"10.1093\/annonc\/mdy096","article-title":"Soft Tissue and Visceral Sarcomas: ESMO\u2013EURACAN Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Choi, J., Manzano, A., Dong, W., Bellone, S., Bonazzoli, E., Zammataro, L., Yao, X., Deshpande, A., Zaidi, S., and Guglielmi, A. (2021). Integrated Mutational Landscape Analysis of Uterine Leiomyosarcomas. Proc. Natl. Acad. Sci. USA, 118.","DOI":"10.1073\/pnas.2025182118"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41467-017-02602-0","article-title":"Integrative Genomic and Transcriptomic Analysis of Leiomyosarcoma","volume":"9","author":"Chudasama","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","article-title":"Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas","volume":"171","author":"Abeshouse","year":"2017","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Fernandes, I., Chehade, R., and MacKay, H. (2024). PARP Inhibitors in Non-Ovarian Gynecologic Cancers. Ther. Adv. Med. Oncol., 16.","DOI":"10.1177\/17588359241255174"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Liu, W., Tong, H., Zhang, C., Zhuang, R., Guo, H., Lv, C., Yang, H., Lin, Q., Guo, X., and Wang, Z. (2020). Integrated Genomic and Transcriptomic Analysis Revealed Mutation Patterns of De-Differentiated Liposarcoma and Leiomyosarcoma. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07456-2"},{"key":"ref_16","first-page":"2072","article-title":"Targeted Next-Generation Sequencing of Cancer Genes Identified Frequent TP53 and ATRX Mutations in Leiomyosarcoma","volume":"7","author":"Yang","year":"2015","journal-title":"Am. J. Transl. Res."},{"key":"ref_17","first-page":"1037","article-title":"Tumor Suppressor Genes and Related Molecules in Leiomyosarcoma","volume":"148","author":"Maestro","year":"1996","journal-title":"Am. J. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1038\/bjc.2012.428","article-title":"Somatic MED12 Mutations in Uterine Leiomyosarcoma and Colorectal Cancer","volume":"107","author":"Kilpivaara","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Astolfi, A., Nannini, M., Indio, V., Schipani, A., Rizzo, A., Perrone, A.M., De Iaco, P., Pirini, M.G., De Leo, A., and Urbini, M. (2020). Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile. Cancers, 12.","DOI":"10.3390\/cancers12082126"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1111\/cas.13613","article-title":"Molecular Biomarkers for Uterine Leiomyosarcoma and Endometrial Stromal Sarcoma","volume":"109","author":"Tsuyoshi","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/bjd\/ljae386","article-title":"Comprehensive Mutational Profiling Identifies New Driver Events in Cutaneous Leiomyosarcoma","volume":"192","author":"Cheema","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1541-7786.MCR-20-0197","article-title":"Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes","volume":"18","author":"Hemming","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/cncr.33542","article-title":"Relationships between Highly Recurrent Tumor Suppressor Alterations in 489 Leiomyosarcomas","volume":"127","author":"Schaefer","year":"2021","journal-title":"Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"155840","DOI":"10.1016\/j.prp.2025.155840","article-title":"Primary Sarcomas of the Bladder and Prostate: A Genomic Landscape Study","volume":"267","author":"Hariri","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"ref_25","first-page":"347","article-title":"New Insights into the Cellular Pathways Affected in Primary Uterine Leiomyosarcoma","volume":"3","author":"Kaur","year":"2006","journal-title":"Cancer Genom. Proteom."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1038\/s41467-021-24677-6","article-title":"Lineage-Defined Leiomyosarcoma Subtypes Emerge Years before Diagnosis and Determine Patient Survival","volume":"12","author":"Anderson","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.06.013","article-title":"Genetic Aberrations in Soft Tissue Leiomyosarcoma","volume":"275","author":"Yang","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00428-024-03994-3","article-title":"Uterine Sarcoma with KAT6B\/A::KANSL1 Fusion: A Molecular and Clinicopathological Study on 9 Cases","volume":"486","author":"Dundr","year":"2025","journal-title":"Virchows Arch."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1158\/1078-0432.CCR-12-2970","article-title":"Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics","volume":"19","author":"Italiano","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000362523","article-title":"Array-CGH Shows Amplification of 8q Including MYC as the Sole Aberration in a Leiomyosarcoma of the Female Lower Genital Tract","volume":"142","author":"Barnabas","year":"2014","journal-title":"Cytogenet. Genome Res."},{"key":"ref_31","first-page":"18","article-title":"Utility of Morphologic Risk Stratification Modeling and Immunohistochemical Surrogates for Key Molecular Alterations in Uterine Leiomyosarcoma","volume":"45","author":"Rehman","year":"2025","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1136\/jclinpath-2015-203561","article-title":"TOP2A Copy Number and TOP2A Expression in Uterine Benign Smooth Muscle Tumours and Leiomyosarcoma","volume":"69","author":"Baiocchi","year":"2016","journal-title":"J. Clin. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/PGP.0000000000000986","article-title":"Dedifferentiated Leiomyosarcoma-Morphology, Immunohistochemistry, and Molecular Findings of a Case and Review of Literature","volume":"43","author":"Kousar","year":"2024","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ijc.31129","article-title":"Integrated Genome Analysis of Uterine Leiomyosarcoma to Identify Novel Driver Genes and Targetable Pathways","volume":"142","author":"Cuppens","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez-Su\u00e1rez, J., Garn\u00e9s-Garc\u00eda, C., Fern\u00e1ndez-Aroca, P., Aparicio-Canada, J., Belandia, B., Ruiz-Hidalgo, M.J., S\u00e1nchez-Prieto, R., and Cimas, F.J. (2025). Specific Transcriptional Signature Dataset of Extracellular Signal-Regulated Kinase 5 in Leiomyosarcoma Derived Cell Lines. BMC Res. Notes, 18.","DOI":"10.1186\/s13104-025-07551-2"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Su, P.-H., Huang, R.-L., Lai, H.-C., Chen, L.-Y., Weng, Y.-C., Wang, C.-C., and Wu, C.-C. (2021). NKX6-1 Mediates Cancer Stem-like Properties and Regulates Sonic Hedgehog Signaling in Leiomyosarcoma. J. Biomed. Sci., 28.","DOI":"10.1186\/s12929-021-00726-6"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41419-025-07850-3","article-title":"RB1 Controls Differentiation through Positive Regulation of Phosphoglycerate Mutases","volume":"16","author":"Kohno","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1158\/1078-0432.CCR-24-1238","article-title":"Genetic Screen in a Preclinical Model of Sarcoma Development Defines Drivers and Therapeutic Vulnerabilities","volume":"30","author":"Freeland","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-24-1160","article-title":"The Impact of Li-Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations","volume":"30","author":"Dermawan","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"a001628","DOI":"10.1101\/mcs.a001628","article-title":"Genomic Profiling of Pelvic Genital Type Leiomyosarcoma in a Woman with a Germline CHEK2: c.1100delC Mutation and a Concomitant Diagnosis of Metastatic Invasive Ductal Breast Carcinoma","volume":"3","author":"Thibodeau","year":"2017","journal-title":"Mol. Case Stud."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Severino, N.P., Waisberg, J., Fragoso, M.C.B.V., de Lima, L.G.C.A., Balsamo, F., Henriques, A.C., Bianco, B., and de Sousa Gehrke, F. (2022). Rectal Leiomyosarcoma as the Initial Phenotypic Manifestation of Li\u2013Fraumeni-like Syndrome: A Case Report and Review of the Literature. J. Med. Case Rep., 16.","DOI":"10.1186\/s13256-022-03671-6"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Roslly, M.Z., Omar, N., and Naim, M.S. (2024). Primary Axillary Vein Leiomyosarcoma in Li-Fraumeni Syndrome. Radiol. Imaging Cancer, 6.","DOI":"10.1148\/rycan.230184"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4103\/0970-1591.166471","article-title":"Urinary Bladder Leiomyosarcoma Following Radiotherapy in a Patient with Bilateral Retinoblastoma: A Case Report","volume":"31","author":"Doddamani","year":"2015","journal-title":"Indian J. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ygyno.2011.10.019","article-title":"Increased Risk of Secondary Uterine Leiomyosarcoma in Hereditary Retinoblastoma","volume":"124","author":"Francis","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1007\/s00261-025-04943-7","article-title":"A Case of Uterine Leiomyosarcoma in a Survivor of Hereditary Retinoblastoma","volume":"50","author":"Kirita","year":"2025","journal-title":"Abdom. Radiol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zhao, L., Jiang, Y., Wang, Y., Bai, Y., Sun, Y., and Li, Y. (2021). Primary Intracranial Leiomyosarcoma Secondary to Glioblastoma: Case Report and Literature Review. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.642683"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Sirbu, B.M., and Cortez, D. (2013). DNA Damage Response: Three Levels of DNA Repair Regulation. Cold Spring Harb. Perspect. Biol., 5.","DOI":"10.1101\/cshperspect.a012724"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1158\/1078-0432.CCR-22-0738","article-title":"Sounding the Alarm on Leiomyosarcoma Recurrence: Role of Circulating Tumor DNA","volume":"28","author":"Kasper","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"100091","DOI":"10.1016\/j.soi.2024.100091","article-title":"DNA Mismatch Repair Deficiency as a Biomarker in Sarcoma","volume":"1","author":"Denu","year":"2024","journal-title":"Surg. Oncol. Insight"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-19-3959","article-title":"Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing","volume":"26","author":"Hensley","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Dall, G., Vandenberg, C.J., Nesic, K., Ratnayake, G., Zhu, W., Vissers, J.H.A., Bed\u0151, J., Penington, J., Wakefield, M.J., and Kee, D. (2023). Targeting Homologous Recombination Deficiency in Uterine Leiomyosarcoma. J. Exp. Clin. Cancer Res., 42.","DOI":"10.1186\/s13046-023-02687-0"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Futagawa, M., Yamamoto, H., Kochi, M., Urakawa, Y., Sogawa, R., Kato, F., Okazawa-Sakai, M., Ennishi, D., Shinozaki, K., and Inoue, H. (2021). Retroperitoneal Leiomyosarcoma in a Female Patient with a Germline Splicing Variant RAD51D c.904-2A\u2009>\u2009T: A Case Report. Hered. Cancer Clin. Pract., 19.","DOI":"10.1186\/s13053-021-00205-x"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.molcel.2018.06.030","article-title":"FANCA Promotes DNA Double-Strand Break Repair by Catalyzing Single-Strand Annealing and Strand Exchange","volume":"71","author":"Benitez","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1038\/s41467-022-30453-x","article-title":"Clinical Sequencing of Soft Tissue and Bone Sarcomas Delineates Diverse Genomic Landscapes and Potential Therapeutic Targets","volume":"13","author":"Nacev","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1158\/1535-7163.MCT-23-0761","article-title":"Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas","volume":"23","author":"Nakazawa","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"110909","DOI":"10.1016\/j.ygeno.2024.110909","article-title":"Dissecting Transposable Elements and Endogenous Retroviruses Upregulation by HDAC Inhibitors in Leiomyosarcoma Cells: Implications for the Interferon Response","volume":"116","author":"Gualandi","year":"2024","journal-title":"Genomics"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"167632","DOI":"10.1016\/j.bbadis.2024.167632","article-title":"Deep Multi-Omics Integration Approach Reveals New Molecular Features of Uterine Leiomyosarcoma","volume":"1871","author":"Falcao","year":"2025","journal-title":"Biochim. Biophys. Acta BBA-Mol. Basis Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"108594","DOI":"10.1016\/j.biopha.2019.01.055","article-title":"CTHRC1 Promotes Wound Repair by Increasing M2 Macrophages via Regulating the TGF-\u03b2 and Notch Pathways","volume":"113","author":"Qin","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1158\/1078-0432.CCR-22-0100","article-title":"Aberrant Activation of Cell-Cycle\u2013Related Kinases and the Potential Therapeutic Impact of PLK1 or CHEK1 Inhibition in Uterine Leiomyosarcoma","volume":"28","author":"Yoshida","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"153920","DOI":"10.1016\/j.prp.2022.153920","article-title":"Cyclin-Dependent Kinase 8 Is an Independent Prognosticator in Uterine Leiomyosarcoma","volume":"235","author":"Yasutake","year":"2022","journal-title":"Pathol. Res. Pract."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/ajcp\/aqw030","article-title":"Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma","volume":"145","author":"Davidson","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Thanopoulou, E., Thway, K., Khabra, K., and Judson, I. (2014). Treatment of Hormone Positive Uterine Leiomyosarcoma with Aromatase Inhibitors. Clin. Sarcoma Res., 4.","DOI":"10.1186\/2045-3329-4-5"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/cam4.2044","article-title":"Hormonal Therapy in Uterine Sarcomas","volume":"8","author":"Zang","year":"2019","journal-title":"Cancer Med."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Maccaroni, E., Lunerti, V., Agostinelli, V., Giampieri, R., Zepponi, L., Pagliacci, A., and Berardi, R. (2022). New Insights into Hormonal Therapies in Uterine Sarcomas. Cancers, 14.","DOI":"10.3390\/cancers14040921"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/path.3986","article-title":"ROR2 Is a Novel Prognostic Biomarker and a Potential Therapeutic Target in Leiomyosarcoma and Gastrointestinal Stromal Tumour","volume":"227","author":"Edris","year":"2012","journal-title":"J. Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"12331","DOI":"10.1038\/s41598-018-30648-7","article-title":"High Expression of EZH2 as a Marker for the Differential Diagnosis of Malignant and Benign Myogenic Tumors","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Yang, Q., Bariani, M.V., Falahati, A., Khosh, A., Lastra, R.R., Siblini, H., Boyer, T.G., and Al-Hendy, A. (2022). The Functional Role and Regulatory Mechanism of Bromodomain-Containing Protein 9 in Human Uterine Leiomyosarcoma. Cells, 11.","DOI":"10.3390\/cells11142160"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"de Almeida, B.C., dos Anjos, L.G., Dobroff, A.S., Baracat, E.C., Yang, Q., Al-Hendy, A., and Carvalho, K.C. (2022). Epigenetic Features in Uterine Leiomyosarcoma and Endometrial Stromal Sarcomas: An Overview of the Literature. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102567"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"804","DOI":"10.55730\/1300-0144.5852","article-title":"NNMT Overexpression Is an Adverse Prognostic Factor in Uterine Leiomyosarcoma","volume":"54","year":"2024","journal-title":"Turk. J. Med. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1158\/1078-0432.CCR-16-0860","article-title":"Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma","volume":"23","author":"Chudasama","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/cncr.10425","article-title":"Tumor Specific Gene Expression Profiles in Human Leiomyosarcoma","volume":"94","author":"Shmulevich","year":"2002","journal-title":"Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e28805","DOI":"10.1002\/pbc.28805","article-title":"A Novel Finding in Pediatric Leiomyosarcoma: Expanding Spectrum of FGFR Rearrangements in Childhood Cancers","volume":"68","author":"Persaud","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"320.e1","DOI":"10.1016\/j.ajog.2019.05.018","article-title":"The Differential Diagnoses of Uterine Leiomyomas and Leiomyosarcomas Using DNA and RNA Sequencing","volume":"221","author":"Mas","year":"2019","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1158\/1541-7786.MCR-18-1075","article-title":"Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma","volume":"17","author":"Davis","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5644\/ama2006-124.248","article-title":"TNS1- ALK Fusion in a Recurrent, Metastatic Uterine Mesenchymal Tumor Originally Diagnosed as Leiomyosarcoma","volume":"48","author":"Lee","year":"2019","journal-title":"Acta Med. Acad."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.2169\/internalmedicine.2879-23","article-title":"LMNA::NTRK1 Fusion-Positive Leiomyosarcoma: Discrepancy between DNA-Based Comprehensive Genomic Profiling and RNA Sequencing","volume":"63","author":"Suzuki","year":"2024","journal-title":"Intern. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/CORR.0000000000002901","article-title":"Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA\/RNA-Based Clinical Sequencing","volume":"482","author":"Hasegawa","year":"2024","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"105555","DOI":"10.1016\/j.esmoop.2025.105555","article-title":"Assessing Targetable NTRK1\/2\/3 Fusions in Mesenchymal Tumors via Whole-Exome RNA Sequencing","volume":"10","author":"Vanacker","year":"2025","journal-title":"ESMO Open"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/PAS.0000000000001055","article-title":"NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma","volume":"42","author":"Chiang","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-pathmechdis-111523-023434","article-title":"Molecular Pathogenesis of Uterine Sarcomas: Mechanisms and Implications for Treatment","volume":"21","author":"Chiang","year":"2026","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"100474","DOI":"10.1016\/j.modpat.2024.100474","article-title":"Expanding the Spectrum of NR4A3 Fusion\u2013Positive Gynecologic Leiomyosarcomas","volume":"37","author":"Mullaney","year":"2024","journal-title":"Mod. Pathol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/PGP.0000000000001089","article-title":"Gynecologic Leiomyosarcoma With Epithelioid Features and PGR::NR4A3 Gene Fusion: First Report in the Vulva","volume":"44","author":"Chadha","year":"2025","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/CORR.0000000000001548","article-title":"Identification of a Novel MAN1A1-ROS1 Fusion Gene Through MRNA-Based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma","volume":"479","author":"Suehara","year":"2021","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"21209","DOI":"10.1074\/jbc.R110.113795","article-title":"EEF1A: Thinking Outside the Ribosome","volume":"285","author":"Mateyak","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/PAS.0000000000001196","article-title":"Novel PLAG1 Gene Rearrangement Distinguishes a Subset of Uterine Myxoid Leiomyosarcoma From Other Uterine Myxoid Mesenchymal Tumors","volume":"43","author":"Benayed","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e23239","DOI":"10.1002\/gcc.23239","article-title":"Novel MIR143HG::PLAG1 Gene Fusion Identified in a Rectal Myxoid Leiomyosarcoma","volume":"63","author":"Wei","year":"2024","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/gcc.22980","article-title":"PLAG1-rearrangement in a Uterine Leiomyosarcoma with Myxoid Stroma and Heterologous Differentiation","volume":"60","author":"Thiryayi","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.pathol.2024.01.009","article-title":"Uterine Myxoid Leiomyosarcoma: Identification of a Novel PLAG1 Fusion Partner","volume":"56","author":"Li","year":"2024","journal-title":"Pathology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1158\/1078-0432.CCR-14-3141","article-title":"Clinically Relevant Molecular Subtypes in Leiomyosarcoma","volume":"21","author":"Guo","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/CCO.0000000000000550","article-title":"Leiomyosarcomas: Whole Genome Sequencing for a Whole Biology Characterization","volume":"31","author":"Chibon","year":"2019","journal-title":"Curr. Opin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neo.2014.12.007","article-title":"Molecular Subtypes of Uterine Leiomyosarcoma and Correlation with Clinical Outcome","volume":"17","author":"Barlin","year":"2015","journal-title":"Neoplasia"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Cope, B.M., Traweek, R.S., Lazcano, R., Keung, E.Z., Lazar, A.J., Roland, C.L., and Nassif, E.F. (2023). Targeting the Molecular and Immunologic Features of Leiomyosarcoma. Cancers, 15.","DOI":"10.3390\/cancers15072099"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"An, Y., Wang, S., Li, S., Zhang, L., Wang, D., Wang, H., Zhu, S., Zhu, W., Li, Y., and Chen, W. (2017). Distinct Molecular Subtypes of Uterine Leiomyosarcoma Respond Differently to Chemotherapy Treatment. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3568-y"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.humpath.2022.12.011","article-title":"Loss of Dystrophin Is Common in Uterine Leiomyosarcoma: A Potential Biomarker for Clinical Application","volume":"134","author":"Vadasz","year":"2023","journal-title":"Hum. Pathol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"152604","DOI":"10.1016\/j.anndiagpath.2025.152604","article-title":"Diagnostic Value of Dystrophin Immunostaining for Histopathologic Diagnosis of Uterine Smooth Muscle Tumors","volume":"81","author":"Nili","year":"2026","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.humpath.2013.11.003","article-title":"Gene Expression Signatures of Primary and Metastatic Uterine Leiomyosarcoma","volume":"45","author":"Davidson","year":"2014","journal-title":"Hum. Pathol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Zhou, M., Bui, N., Rathore, R., Sudhaman, S., George, G.V., Malashevich, A.K., Malhotra, M., Liu, M.C., Aleshin, A., and Ganjoo, K.N. (2022). Feasibility of Longitudinal CtDNA Assessment in Patients with Uterine and Extra-Uterine Leiomyosarcoma. Cancers, 15.","DOI":"10.3390\/cancers15010157"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1158\/1078-0432.CCR-17-3704","article-title":"Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma","volume":"24","author":"Przybyl","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"64","DOI":"10.36401\/JIPO-20-3","article-title":"Identification of Genetic Alterations by Circulating Tumor DNA in Leiomyosarcoma: A Molecular Analysis of 73 Patients","volume":"3","author":"Arshad","year":"2020","journal-title":"J. Immunother. Precis. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00441-020-03296-5","article-title":"FGFR4 Promotes Nuclear Localization of GABP to Inhibit Cell Apoptosis in Uterine Leiomyosarcoma","volume":"383","author":"Zhang","year":"2021","journal-title":"Cell Tissue Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.18632\/oncotarget.28032","article-title":"Epigenetic Signatures Differentiate Uterine and Soft Tissue Leiomyosarcoma","volume":"12","author":"Hasan","year":"2021","journal-title":"Oncotarget"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Cannella, L., Della Monica, R., Marretta, A.L., Iervolino, D., Vincenzi, B., De Chiara, A.R., Clemente, O., Buonaiuto, M., Barretta, M.L., and Di Mauro, A. (2023). The Impact of O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation on the Outcomes of Patients with Leiomyosarcoma Treated with Dacarbazine. Cells, 12.","DOI":"10.3390\/cells12121635"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1089\/ars.2015.6556","article-title":"Disturbed Flow-Induced Endothelial Proatherogenic Signaling Via Regulating Post-Translational Modifications and Epigenetic Events","volume":"25","author":"Heo","year":"2016","journal-title":"Antioxid. Redox Signal."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/bs.ircmb.2025.08.003","article-title":"Epigenetic Regulation via Histone Modifications in Ovarian Cancer","volume":"400","author":"Li","year":"2026","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/03936155251385254","article-title":"Histone Deacetylase in Human Sarcomas","volume":"40","author":"Quan","year":"2025","journal-title":"Int. J. Biol. Markers"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Toyohara, Y., Sone, K., Kumegawa, K., Yamamoto, Y., Hachijo, R., Kukita, A., Taguchi, A., Ikemura, M., Miyamoto, Y., and Tanikawa, M. (2025). Synthetic Lethality from the Combination of a Histone Methyltransferase SUV39H2 Inhibitor and a Poly (ADP-Ribose) Polymerase Inhibitor for Uterine Leiomyosarcoma. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-15267-6"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1002\/ijc.35310","article-title":"Exploration of Histone Protein \u03b3-H2AX as a Prognostic Factor in Soft Tissue Sarcomas and Its Association with Biological Behavior, Immune Cell Environment and Survival in Leiomyosarcoma","volume":"156","author":"Simon","year":"2025","journal-title":"Int. J. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Benna, C., Rajendran, S., Rastrelli, M., and Mocellin, S. (2019). MiRNA Deregulation Targets Specific Pathways in Leiomyosarcoma Development: An in Silico Analysis. J. Transl. Med., 17.","DOI":"10.1186\/s12967-019-1907-2"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"167103","DOI":"10.1016\/j.bbadis.2024.167103","article-title":"Uterine Leiomyosarcoma Cell-Derived Extracellular Vesicles Induce the Formation of Cancer-Associated Fibroblasts","volume":"1870","author":"Nagao","year":"2024","journal-title":"Biochim. Biophys. Acta BBA-Mol. Basis Dis."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"de Almeida, B.C., dos Anjos, L.G., Kagohara, L.T., Al-Hendy, A., Yang, Q., Baracat, E.C., Coutinho-Camillo, C.M., and Carvalho, K.C. (2025). Could Let-7f, MiR-10b, MiR-34a, MiR-181b, and MiR-181d Be Useful Tools as a Target Therapy for Uterine Leiomyosarcoma?. Biomedicines, 13.","DOI":"10.3390\/biomedicines13030560"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"de Almeida, B.C., dos Anjos, L.G., Uno, M., da Cunha, I.W., Soares, F.A., Baiocchi, G., Baracat, E.C., and Carvalho, K.C. (2019). Let-7 MiRNA\u2019s Expression Profile and Its Potential Prognostic Role in Uterine Leiomyosarcoma. Cells, 8.","DOI":"10.3390\/cells8111452"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1111\/j.1582-4934.2008.00541.x","article-title":"Let-7 Repression Leads to HMGA2 Overexpression in Uterine Leiomyosarcoma","volume":"13","author":"Shi","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3892\/or.2023.8523","article-title":"Downregulation of MiR-10b-5p Facilitates the Proliferation of Uterine Leiomyosarcoma Cells: A MicroRNA Sequencing-based Approach","volume":"49","author":"Yoshida","year":"2023","journal-title":"Oncol. Rep."},{"key":"ref_114","first-page":"1547","article-title":"Functionality of the Tumor Suppressor MicroRNA-1 in Malignant Tissue and Cell Line Cells of Uterine Leiomyosarcoma","volume":"38","author":"Stope","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/gcc.22179","article-title":"Differentiating Soft Tissue Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma: A MiRNA Analysis","volume":"53","author":"Guled","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Zoroddu, S., Lucariello, A., De Luca, A., and Bagella, L. (2024). Dysregulation of MiRNAs in Soft Tissue Sarcomas. Cells, 13.","DOI":"10.3390\/cells13221853"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Kourti, A., Kalogiannidis, I., Makedou, K., and Georgiou, E. (2025). MicroRNAs in Uterine Leiomyosarcoma: From Molecular Mechanisms to Clinical Applications. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262210952"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Danielson, L.S., Guijarro, M.V., Menendez, S., Higgins, B., Sun, Q., Mittal, K., Popiolek, D.A., Overholtzer, M., Palmer, G.D., and Hernando, E. (2023). MiR-130b Modulates the Invasive, Migratory, and Metastatic Behavior of Leiomyosarcoma. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0278844"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Schiavon, B.N., Carvalho, K.C., Coutinho-Camillo, C.M., Baiocchi, G., Valieris, R., Drummond, R., da Silva, I.T., De Brot, L., Soares, F.A., and da Cunha, I.W. (2019). MiRNAs 144-3p, 34a-5p, and 206 Are a Useful Signature for Distinguishing Uterine Leiomyosarcoma from Other Smooth Muscle Tumors. Surg. Exp. Pathol., 2.","DOI":"10.1186\/s42047-019-0032-0"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1158\/0008-5472.CAN-21-0356","article-title":"Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma","volume":"81","author":"Kodama","year":"2021","journal-title":"Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/intimm\/dxac014","article-title":"LncRNA EGFR-AS1 Facilitates Leiomyosarcoma Progression and Immune Escape via the EGFR\u2013MYC\u2013PD-L1 Axis","volume":"34","author":"Chen","year":"2022","journal-title":"Int. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"104221","DOI":"10.1016\/j.labinv.2025.104221","article-title":"Comprehensive Analysis of N6-Methyladenosine (M6A) RNA Methylation Regulators in Soft Tissue Leiomyosarcoma","volume":"105","author":"Iwasaki","year":"2025","journal-title":"Lab. Investig."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Yang, Q., and Al-Hendy, A. (2023). The Functional Role and Regulatory Mechanism of FTO M6A RNA Demethylase in Human Uterine Leiomyosarcoma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24097957"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1634\/theoncologist.2018-0448","article-title":"BRCA1\/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma","volume":"24","author":"Seligson","year":"2019","journal-title":"Oncologist"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2022.11.014","article-title":"Elimusertib (BAY1895344), a Novel ATR Inhibitor, Demonstrates in Vivo Activity in ATRX Mutated Models of Uterine Leiomyosarcoma","volume":"168","author":"Harold","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1200\/JCO.23.00402","article-title":"Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)","volume":"41","author":"Ingham","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"101044","DOI":"10.1016\/j.gore.2022.101044","article-title":"Clinical Use of PARP Inhibitor in Recurrent Uterine Leiomyosarcoma with Presence of a Somatic BRCA2 Mutation","volume":"42","author":"Shammas","year":"2022","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"20.251","DOI":"10.7812\/TPP\/20.251","article-title":"Rapid Response of a BRCA2\/TP53\/PTEN-Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report","volume":"25","author":"Pan","year":"2021","journal-title":"Perm. J."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s43032-021-00731-y","article-title":"Evaluation of Hedgehog Pathway Inhibitors as a Therapeutic Option for Uterine Leiomyosarcoma Using the Xenograft Model","volume":"29","author":"Garcia","year":"2022","journal-title":"Reprod. Sci."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Garcia, N., Al-Hendy, A., Baracat, E.C., Carvalho, K.C., and Yang, Q. (2020). Targeting Hedgehog Pathway and DNA Methyltransferases in Uterine Leiomyosarcoma Cells. Cells, 10.","DOI":"10.21203\/rs.3.rs-27677\/v1"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib plus Pembrolizumab in Patients with Advanced Sarcomas Including Alveolar Soft-Part Sarcoma: A Single-Centre, Single-Arm, Phase 2 Trial","volume":"20","author":"Wilky","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.3892\/ijo.2014.2683","article-title":"The Inhibition of Tyrosine Kinase Receptor Signalling in Leiomyosarcoma Cells Using the Small Molecule Kinase Inhibitor PTK787\/ZK222584 (Vatalanib\u00ae)","volume":"45","author":"Gaumann","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10585-013-9574-9","article-title":"The Expression and Characterization of Endoglin in Uterine Leiomyosarcoma","volume":"30","author":"Mitsui","year":"2013","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.ajpath.2011.06.021","article-title":"CSF1 Expression in Nongynecological Leiomyosarcoma Is Associated with Increased Tumor Angiogenesis","volume":"179","author":"Espinosa","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Monga, V., Swami, U., Tanas, M., Bossler, A., Mott, S.L., Smith, B.J., and Milhem, M. (2018). A Phase I\/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas. Cancers, 10.","DOI":"10.3390\/cancers10020053"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Yuan, D., Huang, Y., Cai, Y., Zhang, C., Wang, J.-J., and Zhou, J.-G. (2025). Orosomucoid 1 Is a Potential Prognostic Biomarker for Uterine Sarcoma. Technol. Cancer Res. Treat., 24.","DOI":"10.1177\/15330338251343487"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1158\/0008-5472.CAN-17-2011","article-title":"CD163 Is Required for Protumoral Activation of Macrophages in Human and Murine Sarcoma","volume":"78","author":"Shiraishi","year":"2018","journal-title":"Cancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Guo, Y., Shen, D., Xiao, Y., Wu, C., Chen, M., Yang, L., Li, H., Tong, X., Chen, R., and Li, F. (2025). Single-Cell Profiling Delineates the Tumor Microenvironment and Immunological Networks in Patient-Derived Uterine Leiomyosarcoma. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1653096"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00432-020-03390-9","article-title":"Association of PD-L1 and IDO1 Expression with JAK\u2013STAT Pathway Activation in Soft-Tissue Leiomyosarcoma","volume":"147","author":"Iwasaki","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Pandita, D., Dave, M., and Schulte, B. (2023). PD-1 Inhibition in Metastatic High Tumour Mutational Burden (TMB) Leiomyosarcoma with Clinicopathological Correlates. BMJ Case Rep., 16.","DOI":"10.1136\/bcr-2023-256697"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Lesovaya, E.A., Fetisov, T.I., Bokhyan, B.Y., Senchenko, M.A., Rogozhin, D.V., Maksimova, V.P., Demko, A.N., Belitsky, G.A., Yakubovskaya, M.G., and Kirsanov, K.I. (2025). Genetic Heterogeneity of Undifferentiated Pleomorphic Sarcoma: Is There Potential for Targeted Therapy?. Cancers, 17.","DOI":"10.20944\/preprints202509.1095.v1"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1002\/cncr.30726","article-title":"T-cell Infiltration and Clonality Correlate with Programmed Cell Death Protein 1 and Programmed Death-ligand 1 Expression in Patients with Soft Tissue Sarcomas","volume":"123","author":"Pollack","year":"2017","journal-title":"Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1002\/cncr.30738","article-title":"Immunotherapy with Single Agent Nivolumab for Advanced Leiomyosarcoma of the Uterus: Results of a Phase 2 Study","volume":"123","author":"Barysauskas","year":"2017","journal-title":"Cancer"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s13691-025-00771-0","article-title":"Favorable Response to Nivolumab Combined with Radiotherapy for Retroperitoneal Leiomyosarcoma","volume":"14","author":"Ishihara","year":"2025","journal-title":"Int. Cancer Conf. J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e35609","DOI":"10.1002\/cncr.35609","article-title":"Phase 2 Trial of Avelumab in Combination with Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment (EAGLES, Korean Cancer Study Group UN18-06)","volume":"131","author":"Kim","year":"2025","journal-title":"Cancer"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1158\/1078-0432.CCR-22-3911","article-title":"A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma","volume":"29","author":"Kelly","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.21873\/anticanres.16360","article-title":"A Phase I\/II Investigation of Safety and Efficacy of Nivolumab and nab-Sirolimus in Patients with a Variety of Tumors with Genetic Mutations in the MTOR Pathway","volume":"43","author":"Gordon","year":"2023","journal-title":"Anticancer Res."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Sanborn, R.E., Hamid, O., de Vries, E.G., Ott, P.A., Garcia-Corbacho, J., Boni, V., Bendell, J., Autio, K.A., Cho, D.C., and Plummer, R. (2021). CX-072 (Pacmilimab), a Probody PD-L1 Inhibitor, in Combination with Ipilimumab in Patients with Advanced Solid Tumors (PROCLAIM-CX-072): A First-in-Human, Dose-Finding Study. J. Immunother. Cancer, 9.","DOI":"10.1136\/jitc-2021-002446"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1470-2045(22)00392-8","article-title":"Durvalumab plus Tremelimumab in Advanced or Metastatic Soft Tissue and Bone Sarcomas: A Single-Centre Phase 2 Trial","volume":"23","author":"Somaiah","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1158\/1078-0432.CCR-23-1137","article-title":"Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial","volume":"29","author":"Salawu","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1158\/1078-0432.CCR-23-2250","article-title":"Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-Tissue Sarcomas: Clinical Outcomes and Biological Correlates","volume":"30","author":"Haddox","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41392-025-02278-9","article-title":"Reshaping the Tumor Microenvironment of Cold Soft-Tissue Sarcomas with Anti-Angiogenics: A Phase 2 Trial of Regorafenib Combined with Avelumab","volume":"10","author":"Toulmonde","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1158\/1078-0432.CCR-22-0240","article-title":"A Phase 1\/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma","volume":"28","author":"Wagner","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Tay, T.K.Y., Yeong, J.P.S., Chen, E.X., Sam, X.X., Lim, J.X., and Chan, J.Y. (2022). Soft Tissue Leiomyosarcoma With Microsatellite Instability, High Tumor Mutational Burden, and Programmed Death Ligand-1 Expression Showing Pathologic Complete Response to Pembrolizumab: A Case Report. JCO Precis. Oncol., 6.","DOI":"10.1200\/PO.22.00068"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaoncol.2022.5218","article-title":"Avelumab Plus Talazoparib in Patients With BRCA1\/2-or ATM-Altered Advanced Solid Tumors","volume":"9","author":"Schram","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"197.e1","DOI":"10.1016\/j.ajog.2020.08.028","article-title":"CD70 Antibody-Drug Conjugate as a Potential Therapeutic Agent for Uterine Leiomyosarcoma","volume":"224","author":"Nakae","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1073\/pnas.1121629109","article-title":"Antibody Therapy Targeting the CD47 Protein Is Effective in a Model of Aggressive Metastatic Leiomyosarcoma","volume":"109","author":"Edris","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41598-020-57627-1","article-title":"The Adaptive and Innate Immune Cell Landscape of Uterine Leiomyosarcomas","volume":"10","author":"Manzoni","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","article-title":"Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma","volume":"46","author":"George","year":"2017","journal-title":"Immunity"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"e1655","DOI":"10.1002\/ctm2.1655","article-title":"PI3K\/MTOR Inhibition Induces Tumour Microenvironment Remodelling and Sensitises pS6high Uterine Leiomyosarcoma to PD-1 Blockade","volume":"14","author":"Annibali","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41419-019-1717-8","article-title":"T-Cell Receptor Gene Therapy Targeting Melanoma-Associated Antigen-A4 by Silencing of Endogenous TCR Inhibits Tumor Growth in Mice and Human","volume":"10","author":"Sun","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2023.03.009","article-title":"Uterine Leiomyosarcomas Harboring MAP2K4 Gene Amplification Are Sensitive in Vivo to PLX8725, a Novel MAP2K4 Inhibitor","volume":"172","author":"McNamara","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1038\/bjc.2017.354","article-title":"Expression and Role of TYRO3 and AXL as Potential Therapeutical Targets in Leiomyosarcoma","volume":"117","author":"Lesluyes","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1158\/1535-7163.MCT-09-0125","article-title":"Therapeutic Potential of Hepatocyte Growth Factor\/Scatter Factor Neutralizing Antibodies: Inhibition of Tumor Growth in Both Autocrine and Paracrine Hepatocyte Growth Factor\/Scatter Factor: c-Met-Driven Models of Leiomyosarcoma","volume":"8","author":"Gao","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1158\/1078-0432.CCR-05-2003","article-title":"Oncogenic Property of Acrogranin in Human Uterine Leiomyosarcoma: Direct Evidence of Genetic Contribution in In Vivo Tumorigenesis","volume":"12","author":"Matsumura","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3892\/ijo_00000709","article-title":"Hepatocyte Growth Factor Activator Inhibitors (HAI-1 and HAI-2) Are Potential Targets in Uterine Leiomyosarcoma","volume":"37","author":"Nakamura","year":"2010","journal-title":"Int. J. Oncol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1158\/1078-0432.CCR-23-3720","article-title":"Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair\u2013Deficient Uterine Leiomyosarcoma","volume":"30","author":"Lee","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1159\/000516758","article-title":"Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib","volume":"14","author":"Testa","year":"2021","journal-title":"Case Rep. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Cai, Y., Wang, Y., Yang, L., Huang, Y., Chen, M.-J., Zhang, C., Jin, S.-H., Frey, B., Gaipl, U.S., and Ma, H. (2025). \u03b2-Catenin Is a Potential Prognostic Biomarker in Uterine Sarcoma. Technol. Cancer Res. Treat., 24.","DOI":"10.1177\/15330338251345208"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Mesa, Y., Alba, E., Mart\u00ednez-Barbero, G., Suazo, I., Cuendias, P., Mart\u00edn-Cruces, J., Teul\u00e9-Trull, M., Vega, J.A., Garc\u00eda-Su\u00e1rez, O., and Cobo, T. (2025). Transient Receptor Potential Vanilloid 4 (TRPV4) in the Human Carotid Body. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262110689"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s13402-024-01008-7","article-title":"TRPV4 Drives the Progression of Leiomyosarcoma by Promoting ECM1 Generation and Co-Activating the FAK\/PI3K\/AKT\/GSK3\u03b2 Pathway","volume":"48","author":"Zhou","year":"2025","journal-title":"Cell. Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1158\/1078-0432.CCR-12-0436","article-title":"Dual Targeting of MTOR and Aurora-A Kinase for the Treatment of Uterine Leiomyosarcoma","volume":"18","author":"Demicco","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Babichev, Y., Kabaroff, L., Datti, A., Uehling, D., Isaac, M., Al-awar, R., Prakesch, M., Sun, R.X., Boutros, P.C., and Venier, R. (2016). PI3K\/AKT\/MTOR Inhibition in Combination with Doxorubicin Is an Effective Therapy for Leiomyosarcoma. J. Transl. Med., 14.","DOI":"10.1186\/s12967-016-0814-z"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s10147-013-0563-4","article-title":"Curcumin Targets the AKT\u2013MTOR Pathway for Uterine Leiomyosarcoma Tumor Growth Suppression","volume":"19","author":"Wong","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/IGC.0b013e31828c9581","article-title":"Curcumin Induces Cross-Regulation Between Autophagy and Apoptosis in Uterine Leiomyosarcoma Cells","volume":"23","author":"Bin","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s10147-012-0387-7","article-title":"Epigallocatechin-3-Gallate Potentiates Curcumin\u2019s Ability to Suppress Uterine Leiomyosarcoma Cell Growth and Induce Apoptosis","volume":"18","author":"Kondo","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/5784876","article-title":"Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I\/II Study of Sirolimus in Combination with Ganetespib (SARC023)","volume":"2020","author":"Kim","year":"2020","journal-title":"Sarcoma"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Janku, F., Jegede, O.A., Puhalla, S.L., Konstantinopoulos, P.A., Meric-Bernstam, F., Zwiebel, J.A., Gray, R.J., Wang, X.V., McShane, L.M., and Rubinstein, L.V. (2025). PIK3CB Inhibitor GSK2636771 in Cancers with PTEN Mutation\/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P. JCO Precis. Oncol., 9.","DOI":"10.1200\/PO-25-00265"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ygyno.2016.10.036","article-title":"A Phase 2 Study of Alisertib (MLN8237) in Recurrent or Persistent Uterine Leiomyosarcoma: An NRG Oncology\/Gynecologic Oncology Group Study 0231D","volume":"144","author":"Hyman","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1200\/JCO.2012.45.5766","article-title":"Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy","volume":"31","author":"Demetri","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1158\/2767-9764.CRC-22-0260","article-title":"Phase I Study of MTORC1\/2 Inhibitor Sapanisertib (CB-228\/TAK-228) in Combination with Metformin in Patients with MTOR\/AKT\/PI3K Pathway Alterations and Advanced Solid Malignancies","volume":"4","author":"Subbiah","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Abedin, Y., Gabrilovich, S., Alpert, E., Rego, E., Begum, S., Zhao, Q., Heller, D., Einstein, M.H., and Douglas, N.C. (2022). Gamma Secretase Inhibitors as Potential Therapeutic Targets for Notch Signaling in Uterine Leiomyosarcoma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23115980"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.ajpath.2013.02.035","article-title":"Dual Pten\/Tp53 Suppression Promotes Sarcoma Progression by Activating Notch Signaling","volume":"182","author":"Guijarro","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2015.11.021","article-title":"A First-in-Human Phase I Study of the Oral Notch Inhibitor, LY900009, in Patients with Advanced Cancer","volume":"56","author":"Pant","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/annonc\/mdy244","article-title":"First-in-Human Study of LY3039478, an Oral Notch Signaling Inhibitor in Advanced or Metastatic Cancer","volume":"29","author":"Massard","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.21873\/anticanres.17152","article-title":"Implications of the Hippo Pathway Dysregulation in Uterine Leiomyosarcoma","volume":"44","author":"Kyriazoglou","year":"2024","journal-title":"Anticancer Res."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Onagi, H., Son, R., Oguchi, A., Sano, K., Sasa, K., Hasegawa, N., Akaike, K., Kubota, D., Takagi, T., and Hayashi, T. (2025). Potential Involvement of Myostatin in Smooth Muscle Differentiation in Pleomorphic Leiomyosarcoma. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26167676"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Jin, X., Jiang, C., Gan, X., Zou, X., Li, H., and Zhang, L. (2024). Exploring Causal Relationship between the Lipids, Immune Cells, and Leiomyosarcoma: A Mendelian Randomization and Mediation Analysis. Medicine, 103.","DOI":"10.1097\/MD.0000000000040919"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/bjc.2016.117","article-title":"Inhibition of Bcl-2 Family Members Sensitises Soft Tissue Leiomyosarcomas to Chemotherapy","volume":"114","author":"Gelderblom","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/bjc.2017.187","article-title":"Human Equilibrative Nucleoside Transporter 1 Gene Expression Is Associated with Gemcitabine Efficacy in Advanced Leiomyosarcoma and Angiosarcoma","volume":"117","author":"Vincenzi","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jphs.2022.09.006","article-title":"Stathmin Expression Alters the Antiproliferative Effect of Eribulin in Leiomyosarcoma Cells","volume":"150","author":"Azumi","year":"2022","journal-title":"J. Pharmacol. Sci."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Yahiro, K., Matsumoto, Y., Fukushi, J., Kawaguchi, K., Endo, M., Setsu, N., IIda, K., Fukushima, S., Nakagawa, M., and Kimura, A. (2018). Class III \u03b2-Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line. Anal. Cell. Pathol., 2018.","DOI":"10.1155\/2018\/8987568"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1158\/1078-0432.CCR-22-0518","article-title":"Phase II Clinical Trial of Eribulin\u2013Gemcitabine Combination Therapy in Previously Treated Patients with Advanced Liposarcoma or Leiomyosarcoma","volume":"28","author":"Kim","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-22-2092","article-title":"A Single-Arm Phase Ib\/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma","volume":"28","author":"Chen","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.febslet.2012.05.029","article-title":"Potential Role of LMP2 as an Anti-oncogenic Factor in Human Uterine Leiomyosarcoma: Morphological Significance of Calponin H1","volume":"586","author":"Hayashi","year":"2012","journal-title":"FEBS Lett."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/srep00180","article-title":"Potential Role of LMP2 as Tumor-Suppressor Defines New Targets for Uterine Leiomyosarcoma Therapy","volume":"1","author":"Hayashi","year":"2011","journal-title":"Sci. Rep."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41420-025-02803-3","article-title":"Identification of a Novel Minor-Groove DNA Binder That Represses Mitochondrial Gene Expression and Induces Apoptosis in Highly Aggressive Leiomyosarcoma Cells","volume":"11","author":"Malavasi","year":"2025","journal-title":"Cell Death Discov."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-022-01222-w","article-title":"The Therapeutic Potential of RNA Polymerase I Transcription Inhibitor, CX-5461, in Uterine Leiomyosarcoma","volume":"40","author":"Kang","year":"2022","journal-title":"Investig. New Drugs"},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Abedin, Y., Fife, A., Samuels, C.-A., Wright, R., Murphy, T., Zhang, X., Alpert, E., Cheung, E., Zhao, Q., and Einstein, M.H. (2024). Combined Treatment of Uterine Leiomyosarcoma with Gamma Secretase Inhibitor MK-0752 and Chemotherapeutic Agents Decreases Cellular Invasion and Increases Apoptosis. Cancers, 16.","DOI":"10.3390\/cancers16122184"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00210-016-1291-x","article-title":"Pioglitazone Induces Cell Growth Arrest and Activates Mitochondrial Apoptosis in Human Uterine Leiomyosarcoma Cells by a Peroxisome Proliferator-Activated Receptor \u03b3-Independent Mechanism","volume":"390","author":"Zhao","year":"2017","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"115792","DOI":"10.1016\/j.biopha.2023.115792","article-title":"Ulipristal Acetate, a Selective Progesterone Receptor Modulator, Induces Cell Death via Inhibition of STAT3\/CCL2 Signaling Pathway in Uterine Sarcoma","volume":"168","author":"Hwang","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-079X.2009.00686.x","article-title":"Antineoplastic Effects of Melatonin on a Rare Malignancy of Mesenchymal Origin: Melatonin Receptor-mediated Inhibition of Signal Transduction, Linoleic Acid Metabolism and Growth in Tissue-isolated Human Leiomyosarcoma Xenografts","volume":"47","author":"Dauchy","year":"2009","journal-title":"J. Pineal Res."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/jpi.12298","article-title":"Melatonin Suppression of Aerobic Glycolysis (Warburg Effect), Survival Signalling and Metastasis in Human Leiomyosarcoma","volume":"60","author":"Mao","year":"2016","journal-title":"J. Pineal Res."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Yang, Q., Falahati, A., Khosh, A., Lastra, R.R., Boyer, T.G., and Al-Hendy, A. (2024). Unraveling the Role of Bromodomain and Extra-Terminal Proteins in Human Uterine Leiomyosarcoma. Cells, 13.","DOI":"10.3390\/cells13171443"},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Yang, Q., Falahati, A., Khosh, A., Mohammed, H., Kang, W., Corach\u00e1n, A., Bariani, M.V., Boyer, T.G., and Al-Hendy, A. (2022). Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma. Cells, 11.","DOI":"10.3390\/cells11233801"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"2589666","DOI":"10.1080\/15384047.2025.2589666","article-title":"High-Throughput Screening Identifies the Activity of Histone Deacetylase Inhibitors in Patient-Derived Models of Soft Tissue Sarcoma","volume":"26","author":"Danks","year":"2025","journal-title":"Cancer Biol. Ther."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"19379","DOI":"10.18632\/oncotarget.25056","article-title":"Treatment with Epigenetic Agents Profoundly Inhibits Tumor Growth in Leiomyosarcoma","volume":"9","author":"Hu","year":"2018","journal-title":"Oncotarget"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"106693","DOI":"10.1016\/j.phrs.2023.106693","article-title":"Novel Therapeutic Strategies Targeting UCP2 in Uterine Leiomyosarcoma","volume":"189","author":"Nagao","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3892\/or.2024.8756","article-title":"2-D08 Mediates Notable Anticancer Effects through Multiple Cellular Pathways in Uterine Leiomyosarcoma Cells","volume":"52","author":"Joung","year":"2024","journal-title":"Oncol. Rep."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00018-024-05250-y","article-title":"HMGA1 Regulates Trabectedin Sensitivity in Advanced Soft-Tissue Sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) Study","volume":"81","author":"Moura","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_211","first-page":"2090271","article-title":"A Phase I\/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas","volume":"2016","author":"Judson","year":"2016","journal-title":"Sarcoma"},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Tsimberidou, A.M., Dayyani, F., Sommerhalder, D., Vandross, A.L., Pelster, M.S., Henry, J.T., Perez, C.A., Chakraborty, A., Baysal, M.A., and Chandhasin, C. (2025). Phase 1 Study of Zavondemstat (TACH101), a First-in-Class KDM4 Inhibitor, in Patients with Advanced Solid Tumors. Oncologist, 30.","DOI":"10.1093\/oncolo\/oyaf169"}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/5\/571\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:45:20Z","timestamp":1789479920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/5\/571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":212,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["medsci14050571"],"URL":"https:\/\/doi.org\/10.3390\/medsci14050571","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}